300267.SHE Hunan Er Kang Pharmaceutical
- Market cap
- CNY 6.00B
- P/E
- -
- P/B
- 1.44x
- ROE
- 2.4%
- Dividend yield
- 0.18%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300267.SHE undervalued?
Graham numberThe Graham number of Hunan Er Kang Pharmaceutical cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hunan Er Kang Pharmaceutical fundamental analysis
No fundamental analysis for Hunan Er Kang Pharmaceutical yet.
Hunan Er Kang Pharmaceutical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hunan Er Kang Pharmaceutical
Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for…
Full company profileHunan Er Kang Pharmaceutical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hunan Er Kang Pharmaceutical annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.71B | 2.83B | 2.35B | 2.74B | 2.38B | 2.24B | 1.87B | 1.78B | 1.14B | 1.17B | 1.26B |
| Gross Profit | 1.16B | 1.05B | 821M | 686M | 523M | 319M | 411M | 282M | 290M | 308M | 386M |
| Operating Income | 825M | 589M | 349M | 181M | 218M | -819M | 13.8M | -207M | -371M | 15.7M | 108M |
| EBITDA | 975M | 724M | 402M | 332M | 405M | -645M | 192M | 7.01M | -186M | -179M | 103M |
| Net Income | 795M | 522M | 217M | 159M | 192M | -791M | 45.9M | -195M | -373M | -380M | 96.6M |
| EPS | 0.39 | 0.25 | 0.11 | 0.08 | 0.09 | -0.38 | 0.02 | -0.09 | -0.18 | -0.18 | 0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 5.43B | 5.72B | 6.05B | 6.14B | 6.55B | 5.43B | 5.86B | 5.48B | 5.20B | 4.86B | 5.04B |
| Total Liabilities | 420M | 308M | 409M | 351M | 753M | 558M | 805M | 669M | 798M | 887M | 1.03B |
| Shareholders' Equity | 4.95B | 5.37B | 5.60B | 5.76B | 5.77B | 4.85B | 5.05B | 4.84B | 4.45B | 4.03B | 4.08B |
| Cash & Short-term Investments | 992M | 1.41B | 1.46B | 1.32B | 888M | 762M | 879M | 744M | 819M | 897M | 960M |
| Total Debt | 5.74M | - | 22.8M | - | 463M | 252M | 403M | 343M | 506M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 486M | 687M | 124M | 446M | 179M | 92.7M | 281M | 148M | 167M | 258M | - |
| Capital Expenditure | 1.15B | 259M | 96.7M | 364M | 606M | 349M | 173M | 238M | 196M | 164M | 241M |
| Free Cash Flow | -659M | 428M | 27.2M | 81.6M | -427M | -257M | 108M | -89.8M | -28.9M | 93.7M | -207M |
| Ratios | |||||||||||
| ROE | 16.1% | 9.7% | 3.9% | 2.8% | 3.3% | -16.3% | 0.9% | -4.0% | -8.4% | -9.4% | 2.4% |
| ROA | 14.6% | 9.1% | 3.6% | 2.6% | 2.9% | -14.6% | 0.8% | -3.6% | -7.2% | -7.8% | 1.9% |
| Net Profit Margin | 29.4% | 18.5% | 9.2% | 5.8% | 8.1% | -35.4% | 2.5% | -11.0% | -32.8% | -32.6% | 7.7% |
| Debt to Equity | 0.00x | - | 0.00x | - | 0.08x | 0.05x | 0.08x | 0.07x | 0.11x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hunan Er Kang Pharmaceutical dividends
- Dividend yield
- 0.18%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 9, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 11.1M | 0.01 | - |
| 2024 | CNY 8.42M | 0.00 | - |
| 2023 | CNY 70.1M | 0.03 | - |
| 2022 | CNY 4.73M | 0.00 | 10.3% |
| 2021 | CNY 103M | 0.05 | - |
| 2020 | CNY 20.4M | 0.01 | 10.6% |
| 2019 | CNY 20.6M | 0.01 | 13.0% |
| 2018 | CNY 45.1M | 0.02 | 20.8% |
| 2017 | CNY 44.2M | 0.02 | 8.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on May 10, 2016.
Who owns Hunan Er Kang Pharmaceutical
- Insiders 51.72%
- Institutions 0.51%
- Public & others 47.76%
- Shares outstanding 2.06B
- Free float 1.04B
Hunan Er Kang Pharmaceutical company profile
- Company name
- Hunan Er Kang Pharmaceutical
- Ticker
- 300267.SHE
- ISIN
- CNE100001781
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Sep 27, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,271
- Fiscal year end
- December
- Address
- Liuyang Economic Development Zone, Changsha, China, 410331
- Phone
- 86 731 8465 9108
- Website
- hnerkang.com
About Hunan Er Kang Pharmaceutical
Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutical excipients, such as pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprising of hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate products. Hunan Er-Kang Pharmaceutical Co., Ltd was founded in 2003 and is based in Changsha, China.
Hunan Er Kang Pharmaceutical management
9- Mr. Qingrong SunGM & Non-Independent Director · born 1986
- Ms. Zhao XunCFO & Employee Representative Director · born 1988
- Ms. Xiangyang ShiDeputy GM & Non Independent Director · born 1971
- Mr. Jiang XiaoChief Engineer · born 1986
- Mr. Jishun GuDeputy GM & Board Secretary · born 1966
- Mr. Zhengchun ZhengDeputy General Manager · born 1969
- Mr. Licheng ZhangDeputy General Manager · born 1979
- Mr. Wang HuiDeputy General Manager · born 1984
- Yuhua KuangAccounting Supervisor